Navigation Links
Molecular imaging identifies high-risk patients with heart disease
Date:8/10/2010

Reston, Va.A study published in the August Journal of Nuclear Medicine (JNM) finds that molecular imaginga non-invasive imaging procedurecan identify high-risk patients with potentially life-threatening cardiovascular conditions and help physicians determine which patients are best suited for implantable cardioverter defibrillator (ICD) therapy.

"If the molecular imaging techniques are used for appropriate selection of ICD candidates, not only overuse but also underuse of ICD could be avoided and the assessment may be shown to be more cost-effective," said Kimio Nishisato, M.D., a physician in the cardiology division of Muroram City General Hospital, Muroram, Japan, and corresponding author for the study.

According to researchers from Sapporo University, Sapporo, Japan, the study shows that molecular imaging can play an important role in diagnosing and guiding the treatment strategy for arrhythmia, coronary artery disease and heart failure.

"This research holds significant potential for the detection, diagnosis and treatment of many common cardiovascular conditions," said Tomoaki Nakata, M.D., Ph.D., an associate professor at the Sapporo Medical University School of Medicine and director of the Hokkaido Prefectural Esashi Hospital, Japan. "With molecular imaging, physicians can improve patient care by pinpointing the precise location of the disease in order to eliminate the need for invasive medical devices and unnecessary surgical techniques." Nakata adds that molecular imaging can also reduce unnecessary medical costs by better targeting treatment for each individual patient.

In this study, researchers hypothesized that both the impairment of myocardial perfusion and/or cell viability and cardiac sympathetic innervations are responsible for heart arrhythmia and sudden cardiac death. However, there was no established reliable method, including a molecular imaging technique which is highly objective, reproducible and quantitative. The researchers investigated prognostic implications of cardiac pre-synaptic sympathetic function quantified by cardiac MIBG activity and myocyte damage or viability quantified by cardiac tetrofosmin activity in patients treated with prophylactic use of ICD, by correlating with lethal arrhythmic events which would have been documented during a prospective follow-up. Based on these aspects, the study is the first to show the efficacies of the method for more accurate identification of patients at greater risk of lethal arrhythmias and sudden cardiac death (SCD).

"Sudden cardiac death due to lethal arrhythmia represents an important health care problem in many developed countries," said Ichiro Matsunari, M.D., Ph.D., director of the clinical research department at the Medical & Pharmacological Research Center Foundation, Hakui, Japan, and author of an invited perspective also published in the August JNM. "While implantable cardioverter defibrillator therapy is an effective option over anti-arrhythmic medications to prevent SCD, the balance of clinical benefits, efficacy and risks is still a matter of discussion."

Matsunari adds that better, more precise strategies such as the molecular imaging technique used in this study are needed to identify high-risk patients for SCD, who are most likely to benefit from ICD therapy. SCD is often the first manifestation of an underlying diseasebut one that current treatments such as ICD cannot always detect. Molecular imaging helps guide diagnosis and treatment as well as helps avoid unnecessary ICD treatment.


'/>"/>

Contact: Amy Shaw
ashaw@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Researchers develop magnetic molecular machines to deliver drugs to unhealthy cells
2. New diagnostic chip able to generate single-cell molecular fingerprints for brain tumors
3. Scientists find unsuspected molecular link between obesity and insulin resistance
4. Study Points to Molecular Origins of Celiac Disease
5. Smoking-related colorectal cancer in older women is associated with molecularly defined DNA changes
6. Molecular signatures may aid fight against pediatric liver disease
7. Smoking-related colorectal cancer in older women is associated with molecularly-defined DNA changes
8. SNMs 2010 Annual Meeting reveals latest developments in molecular imaging and nuclear medicine
9. SNM 2010 image of the year: Molecular imaging shows parathyroid disease in greater detail
10. Molecular Devices Relaunches with HiveMind Marketing
11. Molecular imaging detects recurrent prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: